A Study to Better Understand Why Patients Gain Weight After Undergoing Liver Transplantation


  • Study type

  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • Site IRB
    • Rochester, Minnesota: 17-010550
    Sponsor Protocol Number: 17-010550

About this study

The purpose of this study is to understanding the mechanisms of weight gain in patients following liver transplantation, action, and indicate approaches to prevent weight gain.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria:

  • Ability to provide informed consent 
  • Absence of other diseases (structural or metabolic) which could interfere with interpretation of the study results 
  • Body mass index of 18‑45kg/m² 
  • Females must not be pregnant or lactating due to administration of study medications and radiation exposure 

Exclusion Criteria:

  • Several medication classes, particularly those affecting gastrointestinal transit or motor functions, will be excluded including GLP-1 receptor or amylin agonists in patients with diabetes mellitus
    • Stable doses of anti-rejection therapy, Bactrim, Acyclovir/Valganciclovir, proton pump inhibitor, thyroid replacement, estrogen replacement, low-dose aspirin for cardioprotection, and birth control will be permissible
  • Patients on chronic opioids prior to transplant as well as those who continue to utilize any opioid medications (including codeine, tramadol, and tapentadol) at the 4-month visit will be excluded
  • Patients with previous gastric surgery will be excluded

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Kymberly Watt, M.D.

Open for enrollment

Contact information:

Xiao Jing Wang M.D.


More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer